medigraphic.com
ISSN 2078-7170 (Digital)

2014, Número 4

<< Anterior Siguiente >>

CorSalud 2014; 6 (4)


Biomarcadores de daño miocárdico

Rodríguez BS, Almeida GJ, Cruz HJ

Idioma: Español
Referencias bibliográficas: 79
Paginas: 321-333
Archivo PDF: 426.97 Kb.


RESUMEN

El dolor torácico agudo es un síntoma frecuente en los servicios de urgencia. Las determinaciones seriadas de biomarcadores cardíacos en su valoración, ayuda al diagnóstico, a estratificar el riesgo, y tiene implicaciones pronósticas y terapéuticas. Se propone una revisión sobre los biomarcadores de daño miocárdico: troponinas cardíacas, creatinquinasa fracción MB, péptidos natriuréticos y otros nuevos biomarcadores cardíacos; así como su comportamiento en el síndrome coronario agudo y otras cardiopatías. Son una herramienta esencial para la valoración de pacientes con dolor torácico, como complemento de la clínica, fundamentalmente las troponinas cardíacas, por su alta sensibilidad y el valor predictivo negativo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fernández R, Fernández A. Panel multimarcador para pacientes con dolor torácico: ¿está todo di-cho? Rev Esp Cardiol. 2013;66(7):523-5.

  2. Singh V, Martinezclark P, Pascual M, Shaw ES, O’Neill WW. Cardiac biomarkers – The old and the new: a review. Coron Artery Dis. 2010;21(4):244-56.

  3. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chait-man BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20): 2551-67.

  4. Parsonage WA, Cullen L, Younger JF. The approach to patient with possible cardiac chest pain. Med J Aust. 2013;199(1):30-4.

  5. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. J Am Coll Cardiol. 2006;48(1):1-11.

  6. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57(24):2406-8.

  7. Giannitsis E, Katus HA. Cardiac troponin level ele-vations not related to acute coronary syndromes. Nat Rev Cardiol. 2013;10(11):623-34.

  8. Apple FS, Jesse RL, Newby LK, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical mar-kers of acute coronary syndromes. Circulation. 2007;115(13):e352-5.

  9. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkil-de J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guide-lines: Clinical characteristics and utilization of bio-chemical markers of acute coronary syndromes. Circulation. 2007;115(13):e356-75.

  10. 10.de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309(21): 2262-9.

  11. 11.Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31(18):2197-204.

  12. 12.Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33(18):2252-7.

  13. 13.Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, et al. Implementation of a sen-sitive troponin I assay and risk of recurrent myocar-dial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011;305(12): 1210-6.

  14. 14.Saunders JT, Nambi V, de Limos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation. 2011;123(13):1367-76.

  15. 15.Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, et al. 2-Hour accelerated diag-nostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol. 2012;59(23):2091-8.

  16. 16.Gómez-Hospital JA, Cequier Á, Valero J, González-Costello J, Mañas P, Iràculis E, et al. El daño mio-cárdico mínimo durante el intervencionismo coro-nario percutáneo no influye en el pronóstico a largo plazo. Rev Esp Cardiol. 2009;62(6):625-32.

  17. 17.Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, et al. Prognostic value of cardiac troponin I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85(9):1077-82.

  18. 18.Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, et al. Impact of the evaluation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26(15):1494-8.

  19. 19.Nallamothu BK, Chetcuti S, Mukherjee D, Grossman PM, Kline-Rogers E, Werns SW, et al. Prognostic implication of troponin I elevation after percuta-neous coronary intervention. Am J Cardiol. 2003; 91(10):1272-4.

  20. 20.Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol. 2006;48(9):1765-70.

  21. 21.Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin Elevation in Patients with Heart Failure: On Behalf of the Third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33(18):2265-71.

  22. 22.Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol. 2010;56(3):169-76.

  23. 23.Harper RW, Mottram P. Exercise-induced right ventricular dysplasia/cardiomyopathy – An emer-ging condition distinct from arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Lung Circ. 2009;18(3):233-5.

  24. 24.Ector J, Ganame J, van der Merwe N, Adriaenssens B, Pison L, Willems R, et al. Reduced right ventri-cular ejection fraction in endurance athletes pre-senting with ventricular arrhythmias: a quantitative angiographic assessment. Eur Heart J. 2007;28(3): 345-53.

  25. 25.La Gerche A, Robberecht C, Kuiperi C, Nuyens D, Willems R, de Ravel T, et al. Lower than expected desmosomal gene mutation prevalence in en-durance athletes with complex ventricular arrhyth-mias of right ventricular origin. Heart. 2010;96(16): 1268-74.

  26. 26.Fernández A, Pan M, Alfonso F, Aros F, Barrabés JA, Bodí V, et al. Comentarios a la guía de práctica clínica de la ESC para el manejo del síndrome coro-nario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Socie-dad Española de Cardiología. Rev Esp Cardiol. 2012; 65(2):125-30.

  27. 27.Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stel-zig C, Hartwiger S, et al. Early diagnosis of myocar-dial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-67.

  28. 28.Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, et al. Prospective evaluation of the prognostic implications of improved assay per-formance with a sensitive assay for cardiac tropo-nin I. J Am Coll Cardiol. 2010;55(19):2118-24.

  29. 29.Weber M, Bazzino O, Navarro JL, De Miguel R, Salz-berg S, Fuselli JJ, et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J. 2011;162(1):81-8.

  30. 30.Tsounis D, Deftereos S, Bouras G, Giannopoulos G, Anatoliotakis N, Raisakis K, et al. High sensitivity troponin in cardiovascular disease. Is there more than a marker of myocardial death? Curr Top Med Chem. 2013;13(2):201-15.

  31. 31.Baker JO, Reinhold J, Redwood S, Marber MS. Tro-ponins: redefining their limits. Heart. 2011;97(6): 447-52.

  32. 32.Morrow DA. Clinical application of sensitive tropo-nin assays. N Engl J Med. 2009;361(9):913-5.

  33. 33.Bhardwaj A, Truong QA, Peacock WF, Yeo KT, Storrow A, Thomas S, et al. A multicenter com-parison of established and emerging cardiac bio-markers for the diagnostic evaluation of chest pain in the emergency department. Am Heart J. 2011; 162(2):276-82.

  34. 34.Hammerer A, Ploner T, Neururer S, Schratzberger P, Griesmacher A, Pachinger O, et al. High-Sensitivity Cardiac Troponin T Compared With Standard Tro-ponin T Testing on Emergency Department Ad-mission: How Much Does It Add in Everyday Clinical Practice? J Am Heart Assoc [Internet]. 2013 [citado 2013 Oct 11];2(3):e000204. Disponible en: http://jaha.ahajournals.org/content/2/3/e000204.full.pdf+html

  35. 35.Sanchis J, Bardají A, Bosch X, Loma-Osorio P, Marín F, Sánchez PL, et al. Usefulness of high-sensitivity troponin T for the evaluation of patients with acute chest pain and no or minimal myocardial damage. Am Heart J. 2012;164(2):194-200.

  36. 36.Sanchis J, Bardají A, Bosch X, Loma-Osorio P, Marín F, Sánchez PL, et al. Fracción aminoterminal del propéptido natriurético cerebral y troponina ultra-sensible en el dolor torácico agudo de origen incierto. Un subestudio del estudio PITAGORAS. Rev Esp Cardiol. 2013;66(7):532-8.

  37. 37.Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49(8):1331-6.

  38. 38.Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, et al. Visualization of discrete microin-farction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103(23):2780-3.

  39. 39.Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995; 92(6):1558-64.

  40. 40.Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol. 2010;55(14):1403-15.

  41. 41.Szabó G, Rigó J, Nagy B. Physiology and clinical role of natriuretic peptide. Orv Hetil. 2011;152(26): 1025-34.

  42. 42.Jerczyńska H, Pawłowska Z. Natriuretic peptides – Their receptors and role in cardiovascular system. Postepy Biochem. 2008;54(1):35-42.

  43. 43.Nishikimi T, Kuwahara K, Nakao K. Current bio-chemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57(2):131-40. 44.Siemiatkowski A, Jabłonowska A. Natriuretic pep-tides – relevance in intensive care. Anestezjol Intens Ter. 2008;40(2):96-102.

  44. 45.D'Souza SP, Baxter GF. B type natriuretic peptide: a good omen in myocardial ischaemia? Heart. 2003; 89(7):707-9.

  45. 46.Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial in-farction in patients with chest pain and no ST-segment elevation. Eur Heart J. 2005;26(3):234-40.

  46. 47.Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, et al. Patients with acute coro-nary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010;31(16):1993-2005.

  47. 48.Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, et al. Assessment of mul-tiple cardiac biomarkers in non-ST-segment ele-vation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. Eur Heart J. 2011; 32(6):697-705.

  48. 49.Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care. A po-sition statement from the Study Group on Biomar-kers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16):2001-6.

  49. 50.McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, et al. Novel biomarkers in early diagnosis of acute myocardial infarction com-pared with cardiac troponin T. Eur Heart J 2008; 29(23):2843-50.

  50. 51.Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, et al. Improving the primary pre- vention of cardiovascular events by using biomar-kers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60(11):960-8.

  51. 52.Riezebos RK, Ronner E, de Boer BA, Slaats EH, Tijssen JGP, Laarman GJ. Dynamics in N-terminal pro-brain natriuretic peptide concentration in pa-tients with non-ST-elevation acute coronary syn-drome. Am Heart J. 2005;150(6):1255-9.

  52. 53.Truong QA, Bayley J, Hoffmann U, Bamberg F, Schlett CL, Nagurney JT, et al. Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syn-drome diagnosis in emergency department patients with chest pain: from the “Rule Out Myocardial Infarction using Computer Assisted Tomography” (ROMICAT) trial. Am Heart J. 2012;163(6):972-9.

  53. 54.Melki D, Lind S, Agewall S, Jernberg T. Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. Clin Chim Acta. 2012;413(9-10):933-7.

  54. 55.Linskey K, Lewandrowski K. The role of B-type na-triuretic peptide testing in patients with acute coro-nary syndromes. Minerva Cardioangiol. 2012;60(2): 175-82. 56.Nadir MA, Dow E, Davidson J, Kennedy N, Lang CC, Struthers AD. Myocardial ischaemia is associated with an elevated brain natriuretic pepide level even in the presence of left ventricular systolic dys-function. Eur J Heart Fail. 2014;16(1):56-67.

  55. 57.Bayés-Genís A. NTproBNP circulante, un nuevo bio-marcador para el diagnóstico del paciente con dis-nea aguda. Rev Esp Cardiol. 2005;58(10):1142-4.

  56. 58.Lobos JM, Horrillo C, González-González AI, Caste-llanos A, Díaz S, Castellanos J, et al. Validez y utili-dad del péptido ventricular natriurético tipo B (BNP) en la detección de disfunción ventricular iz-quierda en pacientes de alto riesgo en atención primaria. Aten Primaria. 2012;44(1):13-9.

  57. 59.McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. De-veloped in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;-33(14):1787-847.

  58. 60.Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, et al. The role of N-terminal pro brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dys-function in a population at high risk for heart failure. The PROBE-HF Study. J Cardiac Fail. 2009;-15(5):377-84.

  59. 61.Jacob J, Martín-Sánchez FJ, Herrero P, Miró O, Llo-rens P. Los escenarios de utilidad de los péptidos natriuréticos. Aten Primaria. 2012;44(12):739-40.

  60. 62.Llorens P, Martín-Sánchez FJ, González JJ, Herrero P, Jacob J, Bella A, et al. Perfil clínico del paciente con insuficiencia cardiaca aguda atendido en los servicios de urgencias: Datos preliminares del Es-tudio EAHFE (Epidemiology Acute Heart Failure Emergency). Emergencias. 2008;20(3):154-63.

  61. 63.Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert KC. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J. 2008;29(19):2327-35.

  62. 64.Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115(8):962-71.

  63. 65.Heringlake M, Charitos EI, Gatz N, Käbler JH, Beil-harz A, Holz D, et al. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients. J Am Coll Cardiol. 2013;61(6):672-81.

  64. 66.Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115(8):949-52.

  65. 67.Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk pre-diction to risk-guided therapy. Int J Cardiol. 2013; 168(6):5126-34. 68.Zhou L, Zang G, Zhang G, Wang H, Zhang X, John-ston N, et al. MicroRNA and mRNA signatures in ischemia reperfusion injury in heart transplant-ation. PLoS One [Internet]. 2013 [citado 13 Sept 2013];8(11):e79805.[aprox. 14 p.]. Disponible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0079805

  66. 69.Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et al. Circulating microRNAs as novel biomarkers for the early diag-nosis of acute coronary syndrome. J Cardiovasc Transl Res. 2013;6(6):884-98.

  67. 70.Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172-87.

  68. 71.Weber C. MicroRNAs: from basic mechanisms to clinical application in cardiovascular medicine. Ar-terioscler Thromb Vasc Biol. 2013;33(2):168-9.

  69. 72.Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035-9. 73.Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fis-cher A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677-84.

  70. 74.Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Bio-phys Res Commun. 2009;381(4):597-601.

  71. 75.Lindahl B. Acute coronary syndrome - the present and future role of biomarkers. Clin Chem Lab Med. 2013;51(9):1699-706.

  72. 76.Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysre-gulated in human myocardial infarction. Cardiology. 2010;115(3):163-9.

  73. 77.Li C, Pei F, Zhu X, Duan DD, Zeng C. Circulating mi-croRNAs as novel and sensitive biomarkers of acute myocardial Infarction. Clin Biochem. 2012;45(10-11):727-32. 78.Oerlemans MI, Mosterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, et al. Early assessment of acute coronary syndromes in the emergency depart-ment: the potential diagnostic value of circulating microRNAs. EMBO Mol Med. 2012;4(11):1176-85.

  74. 79.Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499-506.

  75. 80.Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659-66.

  76. 81.Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myo-cardial infarction and angina pectoris. BMC Med Genomics [Internet]. 2013 [citado 19 Sept 2013];6: 16[aprox. 9 p.]. Disponible en: http://www.biomedcentral.com/1755-8794/6/16

  77. 82.Van Aelst LN, Heymans S. MicroRNAs as biomarkers for ischemic heart disease. J Cardiovasc Transl Res. 2013;6(4):458-70.

  78. 83.Lin S, Yokoyama H, Rac VE, Brooks SC. Novel bio- markers in diagnosing cardiac ischemia in the emergency department: a systematic review. Re-suscitation. 2012;83(6):684-91.

  79. 84.Amodio G, Antonelli G, Di Serio F. Cardiac biomar-kers in acute coronary syndromes: a review. Curr Vasc Pharmacol. 2010;8(3):388-93.




2020     |     www.medigraphic.com